In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment 

Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking

Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine 

While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients. 

Different approaches are explored, showing good efficacy and mixed tolerability, but further studies are needed to assess their feasibility 

Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments

Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation 

After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types

Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain

Addition of the PD-L1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting, echoing previous data from front-line therapy